Genome Editing Applications | Brussels, Belgium | 2-3 December 2015

Get updates on Therapeutic and Biomedical Applications of CRISPRs, ZFNs, TALENs and other Genome Engineering Technologies

Genome Editing Applications 
2-3 December 2015
Sheraton Airport Hotel
Brussels, Belgium

Biomedical researchers have long strived for a reliable and efficient method of making targeted changes to the genome of living cells. With the advent of CRISPR/Cas9 researchers are now able to explore gene function in a much more thorough and cost-effective way.

This year, Lorenz Mayer from Astrazenca will be giving a presentation on their genome wide target discovery and target validation studies. Ines Royaux from Janssen Phamaceutica will also be giving a presentation touching on the team’s first experience of using genome editing for ex vivo gene therapy. Read on to find out more about what you can expect to learn from the speakers at this year's conference.

Get a sneak peek into the new developments and data the speakers will be sharing during their presentations here.

Informa's Genome Editing Applications 2015 conference, taking place on 2-3 December 2015 in Brussels, will showcase the most up-to-date therapeutic and biomedical applications emerging using CRISPRs, ZFNs, TALENs, AAVs and other genome engineering technologies. From improving lead discovery, validation of targeted cell lines and development of transgenic animal models to therapeutic uses in cell therapy & gene therapy.

This inaugural event in Europe follows the enormous success of Genome Editing Applications in March 2015 in the US from our sister company, IBC Life Sciences.

*Genome Editing Applications is co-located with Cell Therapy Manufacturing and Gene Therapy conferences with a shared exhibition area

So far, across the three conferences, over 120 have confirmed to attend with representation from biopharm, pharma and biotech companies - including Novartis Pharma AG, Glaxosmithkline, CRISPR Therapeutics, Astrazeneca, F Hoffmann-La Roche AG, GSK Pharma, Hitachi LTD, Bluebird BIO, Sanofi Pasteur, Janssen Pharmaceutica NV, Merck & CO., INC., Precision Biosciences, INC.

Hear from influential industry experts such as:

REGISTER FOR AS LITTLE AS £799* TODAY

*Based on standard industry rate Biopharm/Pharma/Biotech 2 day conference pass for one attendee. Not including suppliers/vendors.

Share this article with your social network, just click below to share now!

Share |

Accelerate Your Cell, Gene and Cancer Immunotherapies to Market - Best Rate Ends Friday

Save $400 with the code XB15188BLOG by Friday, July 31 | Register here.

IBC's Cell Therapy Bioprocessing & Commercialization is the most focused conference for cost-effective and efficient cell, gene and immunotherapy approaches that accelerate cell-based product development and production towards commercial success >> Download the full agenda.

Key Topics Include: 
• Applying Genome Editing and Other Disruptive Technologies
• Developing Scalable and Transferrable Manufacturing Processes
• Biopreservation, Cold Chain Management and Patient Delivery
• Developing Successful Business Models
• Fostering Partnerships and Outsourcing Strategies for R&D and Manufacturing
• Pricing, Reimbursement, and Adoption
• Negotiating the Regulatory Pathways to Approval

_______________________________________________________________

Save $400 with the code IMMUNO15BL by Friday, July 31 | Register here.

IBC's Immuno-Oncology is the industry's leading resource for diving into the current issues surrounding efficacy and response rates with first generation immunotherapies to propel the next wave of cancer immunotherapies >> Download the full agenda.

Key Topics Include: 
• Strategies for Combination Therapeutics
• Advances with Checkpoint Inhibitors
• Agnostic Antibody Agents
• Advances in Cancer Vaccines
• Advancing the Next Wave of Cancer Immunotherapies

Share this article with your social network, just click below to share now!

Share |

How will cell therapy change in the next five years?

Joining us in this Cell Therapy Bioprocessing & Commercialization Podcast is Anthony Davies, President of Dark Horse Consulting. Anthony discusses key industry challenges he is seeing, the evolution of the field in the next five years, some exciting new initiatives he is working on, regulatory issues and much more. Below is a brief excerpt from the podcast, be sure to click on the links below to access the complete podcast.

Listen to the Podcast | Access the complete transcript

How do you see the field of cell therapy changing in the next five years? 

I believe strongly that the next five years will bring the first significant drug approval. This will be a transformative moment for the field. A lot of players who are sitting on the wings will move in and there will be a big acceleration. Who will benefit from that the most are the organizations and the entities which have spent the difficult, recent years preparing and positioning themselves the best. 

I think we would do well to look around at this point because it will – in a sense – be the calm before the storm. The companies which are working fervently now preparing themselves to be able to take their drugs all the way to commercialization are the ones who are going to step in to the fast lane when the first big approval comes. And as I said, I do think that the next five years is a very realistic timeframe for this to occur.

[The above was a brief excerpt from the podcast]

Share this article with your social network, just click below to share now!

Share |

Could Gene Therapy Replace the Need for a Heart transplant?

Could gene therapy help avoid a heart transplant?  We’ll soon be one step closer to knowing the answer thanks to a groundbreaking trial in the UK.  Lee Adams, 37, is the first of an eventual 24 patients who will take part in a trial to see if Mydicar, a treatment from U.S. biotech firm Celladon, can help overcome advanced heart failure. 

The treatment is designed to deliver a spike in SERCA2a protein in the heart muscle.  The SERCA2a protein is responsible for making heart muscle contract and low levels have been known to make the heart pump weakly.  The protein will be delivered to the heart via harmless virus.  Researchers plan to take a samples after an initial six month period to measure the presence of the gene.  For those that undergo a subsequent transplant, the researchers will be able to examine the actual heart as well.

Of the 24 patients the study plans to involve, 16 will receive the actual treatment while the other eight are given placebos.  Like Adams, these patients have advanced heart failure and rely on Left Ventricle Assist Devices (LVAD) to keep them alive while they await a transplant. 

The trial, led by Imperial College London and funded by British Heart Foundation as well as Celladon, claims to be the first in the world to investigate the use of gene therapy to correct heart failure. 

Says Professor Sian Harding, who helped develop the treatment, “It's important to remember that the therapy is not correcting a gene defect. We are working much more downstream, which means that no matter what the cause of the heart failure, the therapy should be equally beneficial for patients whether their heart problems stem from genes, lifestyle or the environment or a mixture of all of these."

Adams has a reserved optimism towards the study.  "Of course the best thing that could happen would be for my heart function to show signs of improvement and for the gene therapy to prove to be a 'miracle cure' for myself and other patients. But I'm not building up my hopes too much because, for all I know, I might have had the placebo.”

Here’s to hoping it is the “miracle cure”.

What else is new in the field of cell therapy?  Join us for the Cell Therapy Bioprocessing conference, September 15-16, Boston, MA.  Download the agenda to see what’s on tap.

SAVE 20%* off the standard rate as a reader of this blog. Register here and use code XB14188BLOG.

Sign up for email updates

Check us out on LinkedIn

Follow us on Twitter

Like us on Facebook

*New registrants only

Share this article with your social network, just click below to share now!

Share |